Clicky

Genmab A/S(GMAB) News

Date Title
Apr 15 Transactions in Connection with Share Buy-back Program Genmab
Feb 27 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Feb 27 U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Feb 26 Transactions in connection with share buy-back program
Feb 23 Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Jan 9 GMAB or TECH: Which Is the Better Value Stock Right Now?
Jan 9 TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
Jan 9 TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Jan 2 Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 9 New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Dec 9 New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Dec 7 HRMY or GMAB: Which Is the Better Value Stock Right Now?
Dec 5 Capital Increase in Genmab as a Result of Employee Warrant Exercise
Nov 28 AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
Nov 27 Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
Sep 28 Grant of Restricted Stock Units and Warrants to Employees in Genmab
Sep 28 Diversified Stock Portfolio: 10 Sector ETFs and International ETFs to Buy